Vanda Pharmaceuticals (NASDAQ:VNDA) Director Charles Cliff Duncan Buys 5,803 Shares of Company Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Charles Cliff Duncan acquired 5,803 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was purchased at an average price of $3.80 per share, with a total value of $22,051.40. Following the transaction, the director owned 108,701 shares of the company’s stock, valued at approximately $413,063.80. This trade represents a 5.64% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Charles Cliff Duncan also recently made the following trade(s):

• On Wednesday, November 4th, Charles Cliff Duncan bought 3,447 shares of Vanda Pharmaceuticals stock. The stock was bought at an average price of $3.82 per share, for a total transaction of $13,167.54.
• On Tuesday, November 3rd, Charles Cliff Duncan bought 750 shares of Vanda Pharmaceuticals stock. The shares were acquired at an average cost of $3.80 per share, with a total value of $2,850.00.

Vanda Pharmaceuticals Trading Down 7.5%

Shares of NASDAQ VNDA traded down $0.29 during trading on Thursday, hitting $3.59. 1,239,112 shares of the company were exchanged, compared to its average volume of 1,499,630. Vanda Pharmaceuticals Inc. has a 12-month low of $3.57 and a 12-month high of $9.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.53 and a current ratio of 1.54. The firm has a market capitalization of $217.09 million, a PE ratio of -0.78 and a beta of 0.74. The company has a fifty day moving average price of $4.70 and a 200-day moving average price of $6.16.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.31. The business had revenue of $69.81 million for the quarter, compared to analyst estimates of $69.20 million. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. As a group, equities research analysts expect that Vanda Pharmaceuticals Inc. will post -2.53 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Oppenheimer started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective for the company. Wall Street Zen upgraded Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 31st. B. Riley Financial reiterated a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Thursday, October 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $13.50.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $46,841,000. Renaissance Technologies LLC lifted its holdings in Vanda Pharmaceuticals by 11.2% in the first quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock valued at $25,979,000 after acquiring an additional 378,598 shares during the period. State Street Corp lifted its holdings in Vanda Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock valued at $21,520,000 after acquiring an additional 500,843 shares during the period. AIGH Capital Management LLC boosted its position in shares of Vanda Pharmaceuticals by 37.6% during the 1st quarter. AIGH Capital Management LLC now owns 2,750,000 shares of the biopharmaceutical company’s stock worth $19,002,000 after purchasing an additional 751,569 shares in the last quarter. Finally, Quantinno Capital Management LP boosted its position in shares of Vanda Pharmaceuticals by 25.0% during the 1st quarter. Quantinno Capital Management LP now owns 327,193 shares of the biopharmaceutical company’s stock worth $2,261,000 after purchasing an additional 65,391 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Trending Headlines about Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Director Charles Cliff Duncan bought shares on November 3, 4 and 5, investing about $38,000 in total and increasing his stake. The purchases may signal confidence in Vanda’s prospects. SEC filing
• Neutral Sentiment: HC Wainwright maintained its “Buy” rating and raised its FY2026 loss estimate to $2.45 per share from $3.03, while improving its Q4 2026 estimate. That outlook is partly offset by a wider projected FY2027 loss of $1.02 per share, versus $0.94 previously.
• Negative Sentiment: HC Wainwright lowered its loss-per-share forecasts for Q2, Q3 and Q4 2027, suggesting weaker earnings expectations for much of that year. VNDA is also trading near its 12-month low and below its 50- and 200-day moving averages, reflecting continued share-price weakness.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.